Topic
obesity-treatment
27 stories related to this topic, newest first.
cnbc.comworld7 days ago
Wegovy weight-loss pill now sold privately in UK pharmacies
A once-daily semaglutide tablet is available for private purchase from UK pharmacies. The pill carries the same eligibility rules and dosing schedule as the injectable version and is not yet offered by the NHS.
globalnews.capolitics13 days ago
Medicare Begins Temporary Coverage of GLP-1 Drugs for Obesity
A short-term pilot program allowing Medicare to cover GLP-1 medications for obesity treatment begins July 2 and runs through 2027. Beneficiaries will pay $50 monthly while manufacturers set a $245 price per drug. The program covers obesity treatment only and requires prior author…
fastcompany.comscience15 days ago
Oral GLP-1 drug produces up to 12 percent weight loss in 36-week study
A clinical trial at Northwestern University found that adults taking once-daily oral aleniglipron lost an average of nearly 12 percent of body weight after 36 weeks. The drug is still in development and has not received FDA approval.
Statscience18 days ago
Eli Lilly grants one patient access to obesity drug candidate via FDA program
Eli Lilly and the Food and Drug Administration approved compassionate-use access to retatrutide for a single individual. The decision was discussed on a weekly biotech podcast alongside topics of drug acquisitions and hair-loss treatments.
benzinga.comscience20 days ago
Eli Lilly Provided Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
STAT reported that Eli Lilly supplied its experimental obesity drug retatrutide to a single 79-year-old man via the FDA’s compassionate-use pathway in April. The access drew attention from top health officials. Three sources requested anonymity citing fear of reprisals.
benzinga.comscience20 days ago
Eli Lilly Supplied Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
Stat reported that Eli Lilly supplied its experimental drug retatrutide to a single patient through the FDA’s compassionate-use pathway in April. The request involved a 79-year-old man and drew attention from senior health officials. Retatrutide has produced substantial weight lo…
science22 days ago
Drugmakers test compounds to limit muscle loss during weight reduction
Several pharmaceutical companies are developing medicines that aim to preserve lean mass while patients lose fat. Early human data and repurposed compounds are entering mid-stage trials.
themarketherald.com.auscience35 days ago
Trial Tests Myostatin Inhibitor With Tirzepatide for Lean Mass Retention
A randomized trial examined whether a myostatin inhibitor preserves lean mass during tirzepatide treatment. The study reported 55 percent retention of lean mass compared with placebo.
ER
cnbc.comscience37 days ago
Retatrutide Shows Strong Blood-Sugar and Weight-Loss Benefits in Diabetes Trial With Limited Cardiac Events
New safety figures from Eli Lilly’s TRANSCEND-T2D-1 study were released Saturday at the American Diabetes Association meeting and published in the Lancet.
prnewswire.comscience38 days ago
Rivus Pharmaceuticals Presents Preclinical Non-Human Primate Data on Oral GLP-1 Candidate RV-8451 at ADA Meeting
Rivus Pharmaceuticals announced preclinical results for its oral GLP-1 receptor agonist RV-8451 at the American Diabetes Association's 86th Scientific Sessions on June 5, 2026.
france24.comscience45 days ago
France to Reimburse Patients for Weight-Loss Drugs Starting Mid-June
French Health Minister Stéphanie Rist announced that France will begin reimbursing severely obese patients for two weight-loss medications from mid-June. The plan covers 65 percent of costs, with full coverage for most patients who have additional health conditions.
finance.yahoo.comscience52 days ago
Eli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
benzinga.comscience53 days ago
Eli Lilly Reports Retatrutide Weight Loss Results in Phase 3 Trial
Eli Lilly reported results from a late-stage trial of its obesity drug retatrutide. Patients who stayed on the highest dose lost an average of 28.3 percent of their body weight after 80 weeks.
politics60 days ago
Studies Find Modest Reductions in Migraine Drug Use and Asthma Exacerbations Among People Taking GLP-1RA Medications
Research presented at the European Congress on Obesity in Turkey found that Wegovy was associated with a 7 per cent reduction in triptan use among women with migraines and that GLP-1RA drugs correlated with a 26 per cent drop in asthma exacerbations. The studies drew on Danish he…
rediff.comscience60 days ago
Experimental Quintuple Agonist Outperforms Semaglutide in Mouse Obesity Models
A quintuple agonist developed by researchers at Helmholtz Munich combines GLP-1, GIP and PPAR activity to target five receptor systems. The compound reduced body weight, fat mass and blood sugar more effectively than existing therapies in several mouse models. Scientists caution…
nbcnews.comworld62 days ago
Daily Pill Maintains 70% of Weight Loss vs 38-50% on Placebo One Year After Stopping GLP-1 Injections
A new study shows patients taking daily orforglipron kept more than 70 percent of prior weight loss after one year off jabs, compared with 38-50 percent for those on placebo. The Eli Lilly drug, already available in the US at around $149 per month for the lowest dose, offers a ch…
forbes.comscience62 days ago
Oral Weight Loss Pill Orforglipron Helps Maintain Results After Injectable GLP-1 Drugs
Two randomized studies published in Nature Medicine show patients who switched from tirzepatide or semaglutide to daily oral orforglipron maintained 75 to 79 percent of their weight loss after one year, compared with 38 to 49 percent for those on placebo. The trial involved 376 p…
ER
nypost.comscience62 days ago
Oral Orforglipron Maintains Modest Weight Loss After Stopping Injectables, Trial Finds
A Nature Medicine study found that daily oral orforglipron allowed patients to retain most of their weight reduction after stopping tirzepatide or semaglutide injections. The trial of 376 U.S. participants showed significantly better maintenance than placebo. The drug, approved l…
NA
The Boston Globeworld94 days ago
Reader Responses to GLP-1 Weight Loss Drugs and Insurance Coverage Changes
Readers of The Boston Globe have shared varied opinions on GLP-1 medications for obesity treatment following a February 22 article. Some highlight the drugs' benefits for health conditions beyond weight loss, while others question obesity as a disease and oppose insurance subsidi…
Substrate placeholder — needs reviewworld95 days ago
Study Identifies Genetic Variations Influencing Response to Weight-Loss Drugs Wegovy and Mounjaro
Researchers analyzed genetic data from 15,000 individuals to identify variations linked to weight-loss outcomes and side effects from medications like Wegovy and Mounjaro. The study, published in Nature, found that certain variants affect weight reduction and nausea or vomiting s…
Substrate placeholder — needs reviewworld95 days ago
Eli Lilly Launches Oral GLP-1 Medication Orforglipron for Weight Loss in the United States
Eli Lilly and Company has introduced Foundayo, the brand name for orforglipron, an oral GLP-1 receptor agonist approved for weight management. The pill offers a non-injectable alternative to existing treatments in the growing obesity drug market. Availability begins in the US, ta…
LI
sciencenews.orgscience96 days ago
Genomic and Demographic Data Enable Prediction of GLP-1 Drug Weight Loss Response
Researchers have identified that genomic and demographic data can predict the magnitude of weight loss from GLP-1 drugs. This approach involves analysis by 23andMe. The findings focus on drug response and side effects in obesity treatment.
ER
Substrate placeholder — needs reviewscience96 days ago
Researchers Identify Genetic Variants Linked to Variable Responses to Obesity Drugs
Scientists have identified genetic variants that may explain differences in individual responses to obesity medications. The findings, published in Nature, analyzed data from clinical trials involving drugs like semaglutide. This research highlights the role of genetics in person…
NA
sciencenews.orgscience96 days ago
Genetic Variants Linked to Weight Loss Outcomes and Side Effects from GLP-1 Drugs
A study published in Nature identifies variations in two genes associated with greater weight loss and increased side effects from GLP-1 receptor agonist drugs like Wegovy and Mounjaro. The research, based on data from 15,000 to nearly 28,000 23andMe users, shows modest genetic i…
ST
neurosciencenews.comscience96 days ago
Genetic Variants Linked to Weight Loss Outcomes on GLP-1 Drugs in New Study
A study published in Nature identifies variations in two genes associated with greater weight loss and side effects from GLP-1 receptor agonist drugs like Wegovy and Mounjaro. The research, based on data from 15,000 to 28,000 users, shows these genetic factors contribute modestly…
BU
ST
sciencenews.orgscience96 days ago
Genetic Variations in Two Genes Linked to Weight Loss and Side Effects from GLP-1 Drugs
Research indicates that variations in two genes associated with appetite and digestion can predict greater weight loss in patients using GLP-1 drugs for obesity treatment. These genetic changes also correlate with increased risk of nausea and vomiting as side effects. The finding…
ST
Hunted230 / Wikimedia (CC BY-SA 3.0)world98 days ago
First-Time Users of Weight-Loss Medicines Seek Lower Costs and Greater Convenience from Novo Nordisk and Eli Lilly Pills
Seven doctors specializing in obesity report that Americans beginning weight-loss treatments prioritize reduced costs and improved convenience. These patients are evaluating oral medications from Novo Nordisk and Eli Lilly. The preferences reflect ongoing discussions in the obesi…
RE